Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$0.46 → $0.26 · observed estimates
Citius Oncology Inc (CTOR)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$0.50-8.57%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.46 → 0.26 EPS · FY ending Sep 30, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CTOR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage financial obligations and capital allocation | The company plans to resolve Nasdaq listing issues and manage financial obligations to stabilize operations. | Under Pressure | new dilutive financings announced | New dilutive financing (12.8M shares) vs no further dilution May 2026 warrant inducement agreement for 12.8M shares confirms new dilutive financing. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$0.46 → $0.26 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 22, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making commercial growth story, not a proven durable compounder. The long-term thesis is at a watch stage: nationwide coverage and higher wholesaler units show progress, while recent financial performance remains weak and confidence is low.
The evidence gives no direct valuation measure or clear account of market expectations, so whether CTOR is cheap, fair, or expensive versus peers cannot be assessed. The main expectations gap is between signs of greater LYMPHIR sales activity and the lack of consistent revenue or profit progress.
Near term, fundamentals are mixed: fourth-quarter wholesaler units rose to 792 from 360, but reported revenue fell from the prior quarter and the operating loss remained substantial. Commercial expansion is underway, while the supplied results do not yet show a clear financial payoff; recent performance also sits well below the industry cohort, and the company missed its most recent quarter.
The multi-year view depends on whether LYMPHIR demand and formulary access turn rising sales activity into sustained revenue growth, and whether commercial expansion can support that progress. Near term, a guidance cut or further weakening in jobs data would add pressure, while continued earnings strength and higher guidance from sector bellwethers could support the sector backdrop.
Over the next 1 to 3 years, CTOR’s thesis hinges on converting LYMPHIR’s commercial rollout into stronger financial results; current evidence shows progress in activity but not yet a firm financial trend. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Citius Oncology Inc's published investment case. The stated target is >= $5.6M revenue in Q3 2026. |
| Broken |
| revenue falls below $3.9M in Q4 2026 |
Revenue: $1.494M FY2026-Q3; GAAP. Published target: >= $5.6M revenue in Q3 2026. Target period ends 2026-09-30; this observation covers 2026-Q3. Aug 14, 20261,493,788 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Address Nasdaq listing requirements | The company plans to resolve Nasdaq listing issues and manage financial obligations to stabilize operations. | Under Pressure | bid price remains below $1.00 for 30 consecutive business days | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.16B → $0.13B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-02 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-03 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-04 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-05 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-06 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-07 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-08 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-09 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-10 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-11 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-12 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-13 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-14 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-15 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-16 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-17 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-18 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-19 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-20 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-21 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-22 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-23 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-24 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-25 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-26 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-27 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-28 | $0.46 | $157,408,000 | 1 / 1 |
| 2026-10-29 | $0.26 | $125,926,000 | 1 / 1 |
| 2026-10-30 | $0.26 | $125,926,000 | 1 / 1 |
| 2026-10-31 | $0.26 | $125,926,000 | 1 / 1 |
| 2026-11-01 | $0.26 | $125,926,000 | 1 / 1 |
| 2026-11-02 | $0.26 | $125,926,000 | 1 / 1 |
| 2026-11-03 | $0.26 | $125,926,000 | 1 / 1 |
| 2026-11-04 | $0.26 | $125,926,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.